Clinical Trial Update: Gan & Lee Evaluation of New Biosimilar for Type 1 Lispro [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating a new lispro biosimilar for type 1 diabetes was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 1 Diabetes Mellitus

Drugs mentioned

• Biosimilar lispro (unnamed in snippet) (insulin lispro)

Snippet

Sponsor: Gan and Lee Pharmaceuticals, USA | Conditions: Diabetes Mellitus, Type 1 | Phase 3 | Status: WITHDRAWN